Progenika’s core business is the design and production of genotyping microarrays to be used in the diagnosis and prognosis of genetically complex diseases and prediciting response to therapy.
is a microarray for the diagnosis of Familial Hypercholesterolemia and was released in Europe in June 2004 to become the first CE-marked DNA microarray for routine clinical diagnosis.
was developed to improve the safety of transfusions by genetically characterizing blood group antigens of both donors and recipients.
is a tool for predicting drug response in a broad array of metabolism pathways to improve safety and effectiveness of therapeutic strategies.
With the collaboration of:
